Physician profile
Ryan Stevenson
NPI 1861791964
$7,531.08
in general payments reported to CMS, 2019-2025
30 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $1,192 · 2021: $1,102 · 2022: $1,406 · 2023: $1,068 · 2024: $1,019 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,905.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,256.22 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,727.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,114.39 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $355.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $349.66 | 2019-2022 | |
| Lilly USA, LLC | $240.69 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.72 | 2019-2025 | Jardiance |
| Amgen INC. | $173.64 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $128.59 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $118.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $104.78 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $93.13 | 2022 | |
| Astellas Pharma US INC | $92.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $75.02 | 2019-2021 | |
| Axsome Therapeutics, INC. | $69.58 | 2022-2025 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $58.45 | 2019-2020 | |
| Amarin Pharma, INC. | $56.82 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.81 | 2024-2025 | Trintellix |
| Corcept Therapeutics | $40.65 | 2019-2020 | |
| Allergan, INC. | $36.33 | 2020 | |
| Avanir Pharmaceuticals, INC. | $35.62 | 2019-2020 | |
| Exact Sciences Corporation | $30.04 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $25.49 | 2020 | |
| Abbott Laboratories | $22.51 | 2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $19.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.64 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $17.15 | 2025 | Rexulti |
| Mylan Specialty L.P. | $13.89 | 2023 | Yupelri |
| Dexcom, INC. | $11.75 | 2022 | |
| Pfizer INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.